CLBK vs MRMD: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
CLBK is the larger of the two ($2.93B market cap): the incumbent the market prices for continued execution (14.75x forward earnings, beta 0.27). MRMD is the smaller challenger ($19.08M), still expected to post a loss next year: more room to run, but more to prove. On the numbers, CLBK leads on both counts: faster expected revenue growth (43% vs 1%) and expected profits next year, which MRMD does not have. The case for MRMD rests on its own driver (Branded wholesale growth): if you believe in that, MRMD fits; if you believe in what the numbers show today, CLBK does.
CLBK vs MRMD: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CLBK | MRMD | What it tells you |
|---|---|---|---|
| Market cap | $2.93B | $19.08M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 14.75 | -1.57 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.27 | 1.55 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 79% of range | 2% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 0.92 | 0.45 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how CLBK and MRMD affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CLBK and MRMD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CLBK and MRMD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Columbia Financial (CLBK) do?
Columbia Financial, Inc. (Nasdaq: CLBK) is the Fair Lawn, New Jersey holding company for Columbia Bank, a community and commercial bank offering retail and business deposits, residential and commercial lending, and wealth management across northern and central New Jersey. Before the 2026 transactions it carried roughly $11 billion in total assets, making it a mid-size regional thrift-style franchise concentrated in real-estate-heavy lending. Earnings had been pressured through 2024 by a compressed net interest margin, then recovered through 2025 as funding costs stabilized and the margin widened back toward the low 2 percent range.
What does MariMed (MRMD) do?
MariMed Inc. is a multi-state cannabis operator headquartered in Norwood, Massachusetts. It runs cultivation and production facilities and a chain of dispensaries under the Panacea Wellness and Thrive names, with its core footprint in Massachusetts, Illinois, Maryland, Delaware and Ohio. The company is best known for its branded products rather than its stores: Betty's Eddies fruit chews, Kalm Fusion drinks and tablets, Bubby's Baked, Vibations and the Nature's Heritage flower line. Management says its brands reach about 85% of dispensaries in its core markets, and wholesale to other retailers is a growing share of sales. It has also licensed its brands into Maine and exited Missouri.
CLBK vs MRMD: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- CLBK drivers: Second-step conversion recapitalization; Northfield Bancorp acquisition and scale.
- MRMD drivers: Branded wholesale growth; Delaware and Ohio retail expansion.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: CLBK is a real-estate-concentrated regional lender, so commercial real estate and multifamily credit stress, rising vacancies, or refinancing pressure could drive loan losses. For MRMD, the main risk is leverage relative to a small equity value.
CLBK or MRMD: which should you pick?
If the story you believe is CLBK's (Second-step conversion recapitalization), CLBK is the more direct way to own it; if it is MRMD's (Branded wholesale growth), MRMD is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CLBK and MRMD guides.
CLBK vs MRMD: the full fundamentals
CLBK. Trailing figures mix three standalone quarters with one combined quarter that carried $30.6 million of merger expenses, so they understate the combined franchise: consensus calls for 2026 revenue near $361 million and 2027 revenue near $516 million, with 2027 EPS around $0.74 and fourth-quarter EPS near $0.17. At about $10.84 on November 20, 2026 the stock trades near 14.7x forward earnings and roughly 0.9x book. The three covering analysts carry a mean target around $14.17.
MRMD. On equity alone MariMed looks extremely cheap, at roughly 0.11x trailing sales. That figure misleads because debt is several times the market cap. Adding ~$78.2M of mortgages and notes and subtracting ~$10.4M of cash gives an enterprise value near ~$87M, or about 0.5x sales and roughly 5x an annualized ~$19M of Q3 adjusted EBITDA. That is in the range where small cannabis operators have traded, and it excludes the large income taxes payable, which behave like additional debt. GAAP earnings are negative, so a price-to-earnings ratio is not meaningful.
Headline figures (approximate, November 2026): CLBK shows revenue (ttm) ~$275M (up ~12% YoY in the latest quarter), net income (ttm) ~$49M, q3 2026 net income / eps ~$5.2M / $0.02 GAAP ($40.6M / $0.16 core), net interest margin (q3 2026) ~2.96% (vs 2.44% in Q2 2026); MRMD shows revenue (ttm) ~$167M (Q3 2026 +8.5% YoY), market cap ~$19M, share price (nov 20, 2026) ~$0.05 (YTD -48%), q3 2026 adjusted ebitda ~$4.7M (~10.5% margin).
The bottom line: CLBK vs MRMD
CLBK and MRMD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CLBK and MRMD exposure against your real portfolio. It is not an investment adviser.
Wondering how CLBK or MRMD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Columbia Financial
Ask Walnut's AI anything about CLBK and see how it fits what you own.
FAQ
What is the difference between CLBK and MRMD?
+
Columbia Financial, Inc. MariMed Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CLBK or MRMD the better stock?
+
Neither is universally better. CLBK is the larger incumbent; MRMD is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CLBK or MRMD?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CLBK and MRMD?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CLBK vs MRMD?
+
CLBK: CLBK is a real-estate-concentrated regional lender, so commercial real estate and multifamily credit stress, rising vacancies, or refinancing pressure could drive loan losses. The Northfield integration carries execution risk around systems, staff, deposit retention, and realizing projected cost savings, and merger and conversion charges weigh on near-term reported earnings, as the $30.6 million of merger expenses that cut third-quarter GAAP EPS to $0.02 showed. Newly converted thrifts frequently post low returns on equity until excess capital is deployed, which can make the stock screen expensive on book value. Net interest margin remains sensitive to interest rates and deposit competition, and as a New Jersey and New York bank the franchise is tied to regional economic and housing conditions. After a roughly 55% gain in 2026, the stock trades near 36x trailing and 14.7x forward earnings on Yahoo Finance data; the conversion proceeds enlarged book value, so the shares now sit near 0.9x book, the kind of discount newly converted thrifts often carry, while the high trailing multiple reflects the merger costs that depressed reported earnings. MRMD: The main risk is leverage relative to a small equity value. Mortgages and notes payable were ~$78.2M at September 30, 2026, up from ~$72.7M at year-end 2025, against ~$10.4M of cash and quarterly adjusted EBITDA of only ~$3.6M to ~$4.7M. Covenant breaches could allow lenders to accelerate debt, as the 10-K warns. Tax is a second pressure point: large unpaid income taxes from 280E, ~$7M of disputed IRS liens and a required ~$100,000 monthly escrow tie up cash. Margins are trending down as wholesale prices fall, and a bankrupt wholesale customer already cost a write-off in 2026. The company has posted GAAP net losses (~$7.4M in the first half of 2026 and ~$3.5M more in Q3), and adjusted EBITDA margin fell to 10.5% in Q3 from 12.6% a year earlier. Federal rescheduling for adult use may be delayed or challenged. Dilution is possible through preferred stock, notes and equity raises, and a reverse split can be followed by further price declines, as often happens with OTC names. Finally, the stock is thinly traded on the OTC market, with a 52-week range of roughly ~$0.045 to ~$0.16 and a 45% decline over the three months to November 20, 2026, so quotes can move sharply on small volume.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CLBK or MRMD; figures are approximate and dated (as of November 2026). Verify current data before investing.